MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients

A number of treatments targeting VEGF or mTOR pathways have been approved for metastatic clear cell Renal Cell Carcinoma (ccRCC), but the majority of patients show disease progression after first line therapy with a very low rate of complete or long-term responders. It has been shown that miRs may p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukamowicz-Rajska, Magdalena, Mittmann, Christiane, Prummer, Michael, Zhong, Qing, Bedke, Jens, Hennenlotter, Jörg, Stenzl, Arnulf, Mischo, Axel, Bihr, Svenja, Schmidinger, Manuela, Vogl, Ursula, Blume, Iris, Karlo, Christoph, Schraml, Peter, Moch, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346651/
https://www.ncbi.nlm.nih.gov/pubmed/27738339
http://dx.doi.org/10.18632/oncotarget.12618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346651/
https://www.ncbi.nlm.nih.gov/pubmed/27738339
http://dx.doi.org/10.18632/oncotarget.12618

Ejemplares similares